Phibro: brands it owns and its ownership tree
Phibro (NASDAQ: PAHC) is a publicly listed company headquartered in Teaneck, United States that owns 14 consumer brands.[1][2]
Phibro Animal Health is a Teaneck, New Jersey company whose Animal Health segment sells medicated feed additives, nutritional specialties and vaccines for poultry, swine and cattle, alongside Mineral Nutrition and Performance Products segments. On 31 October 2024 it acquired a portfolio of medicated feed additives from Zoetis, including Aureomycin, Bovatec, Avatec and Deccox, so those brands are now Phibro's, not Zoetis's. Its 10-K for the year to 30 June 2026 reports about 1,465 product registrations worldwide.
-
brands owned
-
1
categories
-
0
acquisitions recorded
-
0
divestitures recorded
Company facts
- Legal name
- Phibro Animal Health Corporation
- Type
- publicly listed company · see all publicly listed company owners
- Headquarters
- 🇺🇸 Teaneck, United States
- Tickers
- NASDAQ: PAHC
- Revenue
- $1.52 billion (2026)[2]
- SEC CIK
- 0001069899
- Website
- www.pahc.com
- Last verified
- · 3 sources
What Phibro's annual report says about its business
Read from Phibro's latest annual filing[1]. Each line gives the sentence the filing uses, copied word for word.
Segments the filing names
- Animal Health, Mineral Nutrition, Performance Products:
We manage our business in three segments Animal Health, Mineral Nutrition, and Performance Products each with its own dedicated management and sales team, for enhanced focus and accountability.
Acquisitions and disposals named in the filing
- Acquired: Zoetis' MFA business (October 2024).
In October 2024, we acquired Zoetis' MFA business, which expanded our offering with several highly-complimentary leading products including Avatec , Bovatec , Aureomycin , Deccox , and Lincomycin .
Phibro in numbers
- Phibro owns 14 consumer brands tracked here across 1 top-level categories; the largest is pet & animal care with 14 brands.[1]
Phibro financial history
Headline figures from Phibro's annual reports filed with the US Securities and Exchange Commission, in USD as reported, fiscal years ending 2021–2026. Revenue moved from $833.4m to $1.52bn, an average of 12.7% a year (calculated).
| Fiscal year ended | Revenue | Operating income | Operating margin | Net income | Total assets | Long-term debt | Filing |
|---|---|---|---|---|---|---|---|
| $1.52bn | $194.4m | 12.8% | $99.7m | $1.5bn | — | 10-K | |
| $1.3bn | $110.5m | 8.5% | $48.3m | $1.36bn | — | 10-K | |
| $1.02bn | $53.3m | 5.2% | $2.42m | $982.2m | $282.3m | 10-K | |
| $977.9m | $71.8m | 7.3% | $32.6m | $971.4m | $311.5m | 10-K | |
| $942.3m | $79m | 8.4% | $49.2m | $931.7m | $272.9m | 10-K | |
| $833.4m | $74.9m | 9.0% | $54.4m | $841.3m | — | 10-K |
Source: SEC XBRL company facts. A dash means the company did not report that line in a form we could read. Figures for a year can be restated in a later filing; the latest filing's number is shown.
Everything Phibro owns
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Full-screen interactive tree → · Download as infographic
Brand portfolio by category
Recent changes to this record
Phibro SEC filings
The documents behind the figures on this page, as listed in the SEC's EDGAR index. Each links to the filing itself.
Annual reports
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
- Annual report, filed (10-K)
Proxy statements
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
- Proxy statement, filed (DEF 14A)
Recent current and quarterly reports
| Filed | Form | What it declares |
|---|---|---|
| 8-K | Results of operations and financial condition | |
| 8-K | Other events | |
| 8-K | Departure or appointment of directors or officers | |
| 8-K | Results of operations and financial condition | |
| 10-Q | Quarterly report | |
| 8-K | Other events | |
| 8-K | Entry into a material agreement; Creation of a direct financial obligation | |
| 8-K | Regulation FD disclosure | |
| 8-K | Departure or appointment of directors or officers | |
| 8-K | Results of operations and financial condition | |
| 10-Q | Quarterly report | |
| 8-K | Other events | |
| 8-K | Departure or appointment of directors or officers; Regulation FD disclosure | |
| 8-K | Results of operations and financial condition; Results of a shareholder vote |
Frequently asked questions
What brands does Phibro own?
Phibro owns 14 consumer brands tracked here, including Avatec, Bovatec, Aureomycin, Stafac, OmniGen and Cygro.
Is Phibro an American company?
Yes. Phibro is headquartered in Teaneck, United States.
Who owns Phibro?
Phibro is a publicly listed company owned by its shareholders; it trades as PAHC on the NASDAQ.
Sources (3) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Phibro Animal Health Corporation Annual Report on Form 10-K filed 2026-08-26 — SEC EDGAR, SEC Form 10-K, published 26 August 2026; retrieved 2 October 2026.
- [2] Phibro Animal Health Corporation: Form 10-K for the year ended 2026-06-30 (revenue) — SEC EDGAR, SEC Form 10-K, published 26 August 2026; retrieved 4 October 2026.
- [3] Phibro Animal Health Corporation Annual Report on Form 10-K filed 2014-09-18 — SEC EDGAR, SEC Form 10-K, published 18 September 2014; retrieved 3 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.